# Transtympanic Ringer's Lactate for the Prevention of Cisplatin Ototoxicity

> **NCT01108601** · PHASE1,PHASE2 · UNKNOWN · sponsor: **McGill University Health Centre/Research Institute of the McGill University Health Centre** · enrollment: 20 (estimated)

## Conditions studied

- Hearing Loss

## Interventions

- **DRUG:** Ringer's Lactate (0.03% Ciprofloxacin)

## Key facts

- **NCT ID:** NCT01108601
- **Lead sponsor:** McGill University Health Centre/Research Institute of the McGill University Health Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-04
- **Primary completion:** 2011-04
- **Final completion:** —
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2010-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01108601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01108601, "Transtympanic Ringer's Lactate for the Prevention of Cisplatin Ototoxicity". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01108601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*